<DOC>
	<DOCNO>NCT01390818</DOCNO>
	<brief_summary>This research trial test combination two experimental drug , MSC1936369B ( Mitogen-activated protein extracellular signal-regulated kinase ( MEK ) Inhibitor ) SAR245409 ( Phosphatidylinositol 3-kinase ( Pi3K ) /Mammalian Target Rapamycin ( mTOR ) inhibitor ) , treatment locally advance metastatic solid tumor . The primary purpose study determine maximum tolerated dose drug combination .</brief_summary>
	<brief_title>Trial MEK Inhibitor PI3K/mTOR Inhibitor Subjects With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Elafin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Subject advance solid tumor approve therapy : Advanced solid tumor diagnose alteration one follow gene ( PTEN , BRAF , KRAS , NRAS , PI3KCA , ErbB1 , ErbB2 , MET , RET , cKIT , GNAQ , GNA11 and/or A histologically cytologically confirm diagnosis one follow solid tumor : pancreatic , thyroid , colorectal , nonsmall cell lung , endometrial , renal , breast , ovarian carcinoma melanoma Subject archive tumor tissue available transfer Sponsor Subject enrol low dose level cohort MTD expansion cohort must tumor available biopsy agree pretreatment ontreatment tumor biopsy Subject measurable evaluable disease response evaluation criterion solid tumor ( RECIST ) v1.1 Subject age great equal ( &gt; = ) 18 year Subjects enrol disease specific expansion cohort must fulfill inclusion/exclusion criterion list follow restriction Inclusion Criterion number 1 : Relapsed refractory Kirsten rat sarcoma viral oncogene homolog ( KRAS ) neuroblastoma RAS viral oncogene homolog ( NRAS ) mutate metastatic nonsmall cell lung cancer ( NSCLC ) approve therapy , Relapsed refractory metastatic triple negative breast cancer define estrogen , progesterone HER2 negative carcinoma breast approve therapy , Relapsed refractory metastatic colorectal cancer ( CRC ) dual KRAS PIK3CA mutation approve therapy , BRAF V600E/K mutate unresectable metastatic melanoma progression BRaf protooncogene , serine/threonine kinase ( BRAF ) inhibitors Other protocoldefined inclusion criterion could apply Subject previously treat PI3K inhibitor MEK inhibitor take treatment due treatment related adverse event Subject receive : Chemotherapy , immunotherapy , hormonal therapy , biologic therapy , anticancer therapy within 28 day trial drug treatment Any investigational agent within 28 day trial drug treatment Extensive prior radiotherapy 30 % bone marrow reserve , prior bone marrow/stem cell transplantation Subject recover toxicity due prior therapy Subject poor organ marrow function define protocol Subject history central nervous system metastasis , unless subject previously treat CNS metastasis Subject history difficulty swallowing , malabsorption chronic gastrointestinal disease Subject history recent major surgery trauma within last 28 day . Subject participate another clinical trial within past 30 day Other protocoldefined exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MEK inhibitor ( Pimasertib )</keyword>
	<keyword>PI3K/mTOR Inhibitor</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Phase I</keyword>
</DOC>